Literature DB >> 12184298

The FDA's drug review process: ensuring drugs are safe and effective.

Michelle Meadows.   

Abstract

Mesh:

Substances:

Year:  2002        PMID: 12184298

Source DB:  PubMed          Journal:  FDA Consum        ISSN: 0362-1332


× No keyword cloud information.
  6 in total

1.  The break-even point: when medical advances are less important than improving the fidelity with which they are delivered.

Authors:  Steven H Woolf; Robert E Johnson
Journal:  Ann Fam Med       Date:  2005 Nov-Dec       Impact factor: 5.166

Review 2.  Efficacy and safety of quinolones vs. other antimicrobials for the treatment of uncomplicated urinary tract infections in adults: a systematic review and meta-analysis.

Authors:  Kaicheng Yan; Man Zhu; Yuting Jia; Jin Wang; Yun Cai
Journal:  Int Urogynecol J       Date:  2021-11-08       Impact factor: 1.932

3.  Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now.

Authors:  Paul A Lapchak
Journal:  Transl Stroke Res       Date:  2013-11-07       Impact factor: 6.829

4.  Quantitative risk-benefit analysis of natalizumab.

Authors:  J P Thompson; K Noyes; E R Dorsey; S R Schwid; R G Holloway
Journal:  Neurology       Date:  2008-07-29       Impact factor: 9.910

5.  Evidentiary Pluralism as a Strategy for Research and Evidence-Based Practice in Rehabilitation Psychology.

Authors:  Jalie A Tucker; Geoffrey M Reed
Journal:  Rehabil Psychol       Date:  2008-08

6.  Development and Psychometric Validation of the FACE-Q Skin, Lips, and Facial Rhytids Appearance Scales and Adverse Effects Checklists for Cosmetic Procedures.

Authors:  Anne F Klassen; Stefan J Cano; Jonathan A Schwitzer; Stephen B Baker; Alastair Carruthers; Jean Carruthers; Anne Chapas; Andrea L Pusic
Journal:  JAMA Dermatol       Date:  2016-04       Impact factor: 10.282

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.